Summit Therapeutics Management

Management Kriterienprüfungen 1/4

Summit Therapeutics' CEO ist Bob Duggan , ernannt in Jul 2022, hat eine Amtszeit von 1.92 Jahren. besitzt direkt 78.12% der Aktien des Unternehmens, im Wert von $4.33B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.9 Jahre bzw. 4 Jahre.

Wichtige Informationen

Bob Duggan

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.9yrs
Eigentum des Geschäftsführers	78.1%
Durchschnittliche Amtszeit des Managements	1.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4yrs

Jüngste Management Updates

Recent updates

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Geschäftsführer

Bob Duggan (79 yo)

1.9yrs

Amtszeit

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Duggan	Co-CEO & Executive Chairman	1.9yrs	keine Daten	78.12% $ 4.4b
Mahkam Zanganeh	Co-CEO, President & Director	1.9yrs	US$20.56m	5.04% $ 280.9m
Manmeet Soni	COO, CFO & Director	less than a year	US$23.97m	0.42% $ 23.6m
Dame Davies	Co-Founder	no data	keine Daten	keine Daten
Bhaskar Anand	Chief Accounting Officer & Head of Finance	less than a year	keine Daten	0.016% $ 868.4k
Abby Murphy	Head of Human Resources	1.2yrs	keine Daten	keine Daten
Divya Chari	Head of Global Clinical Operations	4.3yrs	keine Daten	keine Daten
Dave Gancarz	Chief Business & Strategy Officer?	no data	keine Daten	keine Daten
Betty Chang	Head of Research	3yrs	keine Daten	keine Daten
Fong Clow	Chief Biometrics Officer?	3.4yrs	keine Daten	keine Daten
Shelley Spray	Chief Education & Brand Officer?	1.4yrs	keine Daten	keine Daten
Juthamas Sukbuntherng	Head of Clinical Pharmacology & DMPK?	2.9yrs	keine Daten	keine Daten

1.9yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: SMMTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Duggan	Co-CEO & Executive Chairman	4.5yrs	keine Daten	78.12% $ 4.4b
Mahkam Zanganeh	Co-CEO, President & Director	3.6yrs	US$20.56m	5.04% $ 280.9m
Manmeet Soni	COO, CFO & Director	4.5yrs	US$23.97m	0.42% $ 23.6m
Dame Davies	Co-Founder	no data	keine Daten	keine Daten
Kenneth Clark	Lead Independent Director	2.7yrs	US$334.65k	0% $ 0
Marcel van den Heuvel	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Francesco Muntoni	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Roger Patient	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Edith Sim	Member of Scientific Advisory board	no data	keine Daten	keine Daten
Bob Sim	Member of Scientific Advisory board	no data	keine Daten	keine Daten
Derek Stemple	Member of Scientific Advisory board	no data	keine Daten	keine Daten
Jean-Paul Vincent	Member of Scientific Advisory board	no data	keine Daten	keine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: SMMTDie Vorstandsmitglieder gelten als erfahren (4 Jahre durchschnittliche Amtszeit).

Summit Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Recent updates

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

New major risk - Share price stability

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole

Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Summit Therapeutics to join Russell 3000 Index

Summit Therapeutics Inc. Announces Selected A New Preclinical Candidate, SMT026738

Summit Therapeutics Inc. Elects Dr. Michael Wang as Member of the Board

Summit Therapeutics Inc. Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics Inc. announced that it has received $50 million in funding from Polar Capital LLP and other investors

Summit Therapeutics Inc. announced that it expects to receive $50 million in funding

Summit Therapeutics Inc. Publishes Data from Its Phase 2 Clinical Trial of Ridinilazole Evaluating the Effects of A Narrow-Spectrum (Ridinilazole) or Broad-Spectrum Antibiotic

Geschäftsführer